|
1
|
Siegel RL, Miller KD and Jemal A: Cancer
statistics, 2017. CA Cancer J Clin. 67:7–30. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Miller KD, Siegel RL, Lin CC, Mariotto AB,
Kramer JL, Rowland JH, Stein KD, Alteri R and Jemal A: Cancer
treatment and survivorship statistics, 2016. CA Cancer J Clin.
66:271–289. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Takai Y, Miyoshi J, Ikeda W and Ogita H:
Nectins and nectin-like molecules: Roles in contact inhibition of
cell movement and proliferation. Nature reviews. Nat Rev Mol Cell
Biol. 9:603–615. 2008. View
Article : Google Scholar : PubMed/NCBI
|
|
4
|
Rajc J, Gugić D, Fröhlich I, Marjanović K
and Dumenčić B: Prognostic role of Nectin-4 expression in luminal B
(HER2 negative) breast cancer. Pathol Res Pract. 213:1102–1108.
2017. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Reymond N, Fabre S, Lecocq E, Adelaide J,
Dubreuil P and Lopez M: Nectin4/PRR4, a new afadin-associated
member of the nectin family that trans-interacts with nectin1/PRR1
through V domain interaction. J Biol Chem. 276:43205–43215. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Brancati F, Fortugno P, Bottillo I, Lopez
M, Josselin E, Boudghene-Stambouli O, Agolini E, Bernardini L,
Bellacchio E, Iannicelli M, et al: Mutations in PVRL4, encoding
cell adhesion molecule nectin-4, cause ectodermal
dysplasia-syndactyly syndrome. Am J Hum Genet. 87:265–273. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Derycke MS, Pambuccian SE, Gilks CB,
Kalloger SE, Ghidouche A, Lopez M, Bliss RL, Geller MA, Argenta PA,
Harrington KM and Skubitz AP: Nectin 4 overexpression in ovarian
cancer tissues and serum: Potential role as a serum biomarker. Am J
Clin Pathol. 134:835–845. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Fabre-Lafay S, Monville F, Garrido-Urbani
S, Berruyer-Pouyet C, Ginestier C, Reymond N, Finetti P, Sauvan R,
Adélaïde J, Geneix J, et al: Nectin-4 is a new histological and
serological tumor associated marker for breast cancer. BMC Cancer.
7:732007. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Takano A, Ishikawa N, Nishino R, Masuda K,
Yasui W, Inai K, Nishimura H, Ito H, Nakayama H, Miyagi Y, et al:
Identification of nectin-4 oncoprotein as a diagnostic and
therapeutic target for lung cancer. Cancer Res. 69:6694–6703. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Bianconi D, Unseld M and Prager GW:
Integrins in the spotlight of cancer. Int J Mol Sci. 17(pii):
E20372016. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Duro-Castano A, Gallon E, Decker C and
Vicent MJ: Modulating angiogenesis with integrin-targeted
nanomedicines. Adv Drug Deliv Rev. 119:101–119. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Vartanian A, Stepanova E, Grigorieva I,
Solomko E, Belkin V, Baryshnikov A and Lichinitser M: Melanoma
vasculogenic mimicry capillary-like structure formation depends on
integrin and calcium signaling. Microcirculation. 18:390–399. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Camorani S, Crescenzi E, Gramanzini M,
Fedele M, Zannetti A and Cerchia L: Aptamer-mediated impairment of
EGFR-integrin αvβ3 complex inhibits vasculogenic mimicry and growth
of triple-negative breast cancers. Sci Rep. 7:466592017. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Velez DO, Tsui B, Goshia T, Chute CL, Han
A, Carter H and Fraley SI: 3D collagen architecture induces a
conserved migratory and transcriptional response linked to
vasculogenic mimicry. Nat Commun. 8:16512017. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Maniotis AJ, Folberg R, Hess A, Seftor EA,
Gardner LM, Pe'er J, Trent JM, Meltzer PS and Hendrix MJ: Vascular
channel formation by human melanoma cells in vivo and in vitro:
Vasculogenic mimicry. Am J Pathol. 155:739–752. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Qiao L, Liang N, Zhang J, Xie J, Liu F, Xu
D, Yu X and Tian Y: Advanced research on vasculogenic mimicry in
cancer. J Cell Mol Med. 19:315–326. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Wei L, Jin Z, Yang S, Xu Y, Zhu Y and Ji
Y: TCGA-assembler 2: Software pipeline for retrieval and processing
of TCGA/CPTAC data. Bioinformatics. 34:1615–1617. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Benson AB III, Venook AP, Cederquist L,
Chan E, Chen YJ, Cooper HS, Deming D, Engstrom PF, Enzinger PC,
Fichera A, et al: Colon cancer, version 1.2017, NCCN clinical
practice guidelines in oncology. J Natl Compr Canc Netw.
15:370–398. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Sadeghi MR, Jeddi F, Soozangar N, Somi MH,
Shirmohamadi M, Khaze V and Samadi N: Nrf2/P-glycoprotein axis is
associated with clinicopathological characteristics in colorectal
cancer. Biomed Pharmacother. 104:458–464. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Kurita S, Ogita H and Takai Y: Cooperative
role of nectin-nectin and nectin-afadin interactions in formation
of nectin-based cell-cell adhesion. J Biol Chem. 286:36297–36303.
2011. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Pavlova NN, Pallasch C, Elia AE, Braun CJ,
Westbrook TF, Hemann M and Elledge SJ: A role for PVRL4-driven
cell-cell interactions in tumorigenesis. ELife. 2:e003582013.
View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Siddharth S, Goutam K, Das S, Nayak A,
Nayak D, Sethy C, Wyatt MD and Kundu CN: Nectin-4 is a breast
cancer stem cell marker that induces WNT/β-catenin signaling via
Pi3k/Akt axis. Int J Biochem Cell Biol. 89:85–94. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Cao Z, Bao M, Miele L, Sarkar FH, Wang Z
and Zhou Q: Tumour vasculogenic mimicry is associated with poor
prognosis of human cancer patients: A systemic review and
meta-analysis. Eur J Cancer. 49:3914–3923. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Zhang J, Qiao L, Liang N, Xie J, Luo H,
Deng G and Zhang J: Vasculogenic mimicry and tumor metastasis. J
BUON. 21:533–541. 2016.PubMed/NCBI
|
|
25
|
Sun B, Zhang D, Zhao N and Zhao X:
Epithelial-to-endothelial transition and cancer stem cells: Two
cornerstones of vasculogenic mimicry in malignant tumors.
Oncotarget. 8:30502–30510. 2017.PubMed/NCBI
|
|
26
|
Dey N, De P and Brian LJ: Evading
anti-angiogenic therapy: Resistance to anti-angiogenic therapy in
solid tumors. Am J Transl Res. 7:1675–1698. 2015.PubMed/NCBI
|
|
27
|
Chen MB, Lamar JM, Li R, Hynes RO and Kamm
RD: Elucidation of the roles of tumor integrin beta1 in the
extravasation stage of the metastasis cascade. Cancer Res.
76:2513–2524. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Xu Z, Zou L, Ma G, Wu X, Huang F, Feng T,
Li S, Lin Q, He X, Liu Z and Cao X: Integrin β1 is a critical
effector in promoting metastasis and chemo-resistance of esophageal
squamous cell carcinoma. Am J Cancer Res. 7:531–542.
2017.PubMed/NCBI
|
|
29
|
Zhang Y, Liu S, Wang L, Wu Y, Hao J, Wang
Z, Lu W, Wang XA, Zhang F, Cao Y, et al: A novel PI3K/AKT signaling
axis mediates Nectin-4-induced gallbladder cancer cell
proliferation, metastasis and tumor growth. Cancer Lett.
375:179–189. 2016. View Article : Google Scholar : PubMed/NCBI
|
